



WEEKLY FINANCIAL MARKET OVERVIEW

period 09.11.2020.-15.11.2020.

Financial Markets	Price	5D,%	1M,%	YTD,%	1YR,%
S&P 500 INDEX	3 585.15	2.16	2.91	10.97	14.89
DOW JONES INDUS. AVG	29 479.81	4.08	3.05	3.30	5.27
STOXX Europe 600 Index	385.18	5.13	4.82	-7.37	-5.14
DAX INDEX	13 076.72	4.78	1.30	-1.30	-1.25
RTS Index	1 548.92	4.20	8.38	-20.73	-15.29
SHANGHAI SE COMPOSITE	3 310.10	-1.07	0.04	9.43	15.44
NIKKEI 225	25 385.87	4.30	10.66	9.51	11.17
MSCI WORLD	2 529.29	1.09	3.65	7.24	10.80
European Renewable Energy Index	2 251.24	5.12	5.70	56.94	66.91
Chicago Board Options Exchange Volatility Index (VIX)	23.10	-16.24	-15.72	67.63	91.70

Commodities	Price	5D,%	1M,%	YTD,%	1YR,%
GOLD Futures	1 886.20	1.82	-0.66	23.97	28.58
SILVER Futures	24.78	5.25	2.21	39.19	47.19
LME COPPER 3MO (\$)	6 934.00	0.52	4.34	13.10	19.67
LME NICKEL 3MO (\$)	15 936.00	3.45	5.66	13.31	3.33
Brent	42.78	2.10	0.84	-34.41	-31.61
WTI	40.13	1.07	-0.39	-33.31	-29.45




Currencies	Price	5D,%	1M,%	YTD,%	1YR,%
EUR/USD	1.18	0.25	1.11	5.51	6.91
USD/JPY	104.63	0.87	0.81	3.85	3.86
GBP/USD	1.32	0.58	2.34	-0.35	1.93

Money Market	Price	5D,%	1M,%	YTD,%	1YR,%
LIBOR USD 3M	0.22	7.83	-6.28	-88.37	-88.38
LIBOR EUR 3M	-0.54	-0.03	-1.59	-30.00	-23.24
EURIBOR 3M	-0.51	-0.20	-1.18	-34.20	-27.86
EUR SWAP (EONIA) 3M	-0.48	1.53	-0.10	-8.63	-6.47

Government Bonds	Yield	5D,%	1M,%	YTD,%	1YR,%
US Government Bonds 10 YR (USD)	0.90	-4.01	18.90	-53.77	-51.58
German Government Bonds 10 YR (EUR)	-0.55	11.92	1.62	-195.68	-82.33
UK Government Bonds 10 YR (GBP)	0.34	23.36	41.42	-58.88	-55.47
Swiss Government Bonds 10 YR (CHF)	-0.48	6.98	1.64	-1.91	-1.91
Japan Government Bonds 10 YR (JPY)	0.02	33.33	-20.00	180.00	140.00

Main events of the previous week

At the beginning of the previous week, it became known that scientists have managed to develop the first truly effective vaccine. It was the developers of Pfizer and BioNTech who succeeded in this. 43,500 people from six countries took part in clinical trials and they did not have any side effects. The developers plan to apply for an emergency certification procedure so that the new vaccine could be used by the end of November. This vaccine, together with the latest therapies, is considered as the best opportunity to end the limitations that have been imposed this year to stop the spread of coronavirus. About a dozen different vaccines are currently in the final stage of clinical trials, but this is the first one that has proven to be highly effective. Clinical trials in the US, Germany, Brazil, Argentina, South Africa and Turkey have shown that 90% protection against coronavirus was achieved 7 days after the second injection. Pfizer is confident that they will be able to create 50 million doses of vaccine by the end of the year, and by the end of 2021 - about 1.3 billion. Unfortunately, there also are some difficulties, since the new vaccine must be stored at a very low temperature - 80 ° C. The duration of its action is also questionable. In addition, the development companies have not yet provided data on the effectiveness of the vaccine for different age groups. So far, the data presented for the vaccine cannot be considered complete. It is based on the treatment results of the first 94 volunteers diagnosed with Covid-19. More accurate data on its effectiveness will appear after all the results are processed. Developers say they will have enough information by the third week of November to apply to regulatory authorities for formal approval of the vaccine. Until then, national vaccination campaigns cannot start.



Economic data

US. Consumer price index in October remained at the level of September, while the annual inflation rate was 1.2%. The growth of the core inflation rate excluding food and energy in October amounted to 1.6% yoy.

The number of initial jobless claims for the week was registered in the amount of 709 thousand, which is 48 thousand less than the week before and 26 thousand less than predicted by analysts.

Eurozone. According to the recalculation, GDP in the second quarter grew by 12.6% compared to the first quarter of 2020, while in the second quarter the decline was 4.4% relative to the second quarter of 2019.

China. The consumer price index in October decreased by 0.3% versus September, while the annual inflation rate was 0.5%.

Key events this week

- On Monday, China will report on retail trade, industrial production and labor market conditions in October.
- On Tuesday, retail and industrial production for October will be reported in the US.
- On Wednesday, the final data on inflation in October will be known in the Eurozone, and the change in oil reserves for the week will become known in the US.
- On Thursday, the US will report on home sales in the primary market, as well as the number of initial jobless claims for the week.

Responsibility disclaimer regarding financial market reviews

The author of this review is JSC Baltic International Bank (Registration No. 40003127883, legal address: 43 Kalēju Street, Riga, LV-1050, Latvia) (the 'Bank'). This review was created for informational purposes only and cannot be considered as an offer or recommendation for the purchase, holding or sale of securities, or as an investment recommendation, investment research or investment advice. Investment services, including investments in financial instruments, are associated with the risks described in the document 'Characteristics of Financial Instruments and Inherent Risks'. The document can be found on the home page of Baltic International Bank at <https://www.bib.eu/en/documents>. The Bank and the persons associated with it and its employees shall not be liable for direct or indirect losses of the persons who have read this review as well as for the penalties imposed on said persons even if there is a warning about their possible application. Those who have read this review should fully base their investments on their own assessment of the circumstances affecting investments. Responsibility for the decisions made based on the information contained in this review lies entirely and exclusively with the person who has read this review. The information referred to in this review was obtained from publicly available sources, and the Bank and its employees shall not be responsible for the accuracy and completeness of the information received and provided in this review, as well as for inaccuracies or errors made in this review. The Bank may also have information not reflected in this review. The issuers mentioned in this review are not familiar with its contents. The Bank notifies that at the time of writing this review as well as in the future the Bank may enter into legal relations with the companies named in this review. In this regard, the Bank may have a conflict of interest that affects the objectivity of this review. The Bank reserves the right to conduct transactions in securities and financial instruments specified in this review not being guided by the information specified in it. The Bank's Compliance Control Department ensures that the Bank's employees avoid conflicts of interest. The Bank is supervised by the Financial and Capital Market Commission of the Republic of Latvia.